In February, the FDA approved the first and only oral treatment for eosinophilic esophagitis (EoE) that contains the active pharmaceutical ingredient (API) budesonide at a strength of 2 mg/10mL, which may sound familiar to many compounders.1 How does this affect compounders and what other potential options are available to patients?

Imagine having a clinical support team on-call 24/7, who is able to resolve tricky formula issues, research literature for new compounding developments, provide marketing and business support, and navigate esoteric government agency regulations. If you’re a PCCA member with clinical services access, you don’t have to imagine it — this “extension of your pharmacy staff” already exists! Members without clinical services access may not know what they’re missing — all for just $27 a day.

On November 1, 2023, revisions to USP Chapter 795 and Chapter 797 became official and made USP 800 compendially applicable and potentially enforceable. However, other regulatory agencies — including state boards of pharmacy and the FDA — may impact whether USP 800 is enforceable in your pharmacy.